Thrombus - 2014


What do we know about antiphospholipid syndrome?
Karen Breen
pp 1-5
Antiphospholipid syndrome (APS) is a complex autoimmune disorder characterised by thrombosis and/or pregnancy morbidity in association with the persistent presence of antiphospholipid antibodies. APS is often associated with other autoimmune diseases, usually systemic lupus erythematosus (previously referred to as secondary APS), but it can occur in patients without an underlying systemic autoimmune disease (previously known as primary APS).
Comment: To monitor or not to monitor?
Peter Rose
pp 2-2
The holy grail of anticoagulant therapy has always been to develop effective agents without the need for routine laboratory monitoring. Studies of the recently developed direct oral inhibitors have used standard dosing regimens for comparison with dose-adjusted warfarin, requiring routine laboratory monitoring. These studies have all focused on clinical outcomes of recurrent thrombosis and bleeding events. On this basis, new drugs have now been licensed and approved by NICE for stroke thromboprophylaxis for non-valvular atrial fibrillation and management of venous thromboembolic disease.
A guide to laboratory tests for antiphospholipid syndrome
Ian Jennings
pp 6-8
The association of antiphospholipid syndrome (APS) with venous thromboembolic disease, arterial occlusive events and pregnancy morbidity, and the consequent requirements for appropriate patient management, highlight the need for an accurate diagnosis of APS.
Review of the revised NICE guideline on atrial fibrillation
David Fitzmaurice
pp 9-10
In June 2014, the National Institute for Health and Care Excellence published a revised clinical guideline for atrial fibrillation (CG180).
Anticoagulation in Practice Conference 2014
Ellen Murray
pp 11-12
A fantastic line-up of speakers attended the Anticoagulation in Practice (AiP) Conference 2014, which took place on 5 and 6 of June at the University of Birmingham.
A survey of current practices in international normalised ratio point-of-care monitoring
Dianne P Kitchen, Steve Kitchen, Ian Jennings, Timothy AL Woods, Ellen T Murray, Isobel D Walker, David A Fitzmaurice
pp 13-15
Over the past ten years, there has been an increase in international normalised ratio testing using point-of-care (POC) coagulometers. This increase has led to a diverse range of users and variability of practice in the delivery of this testing. The relevant guideline for and review of POC testing state that both external quality assurance and internal quality control should be undertaken to ensure valid and reliable results are obtained.

Thrombus was previously supported by Bayer from 2014 to 2016, by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1369-8117 (Print)  ISSN 2045-7855 (Online)

Site Map | company profile | contact us | testimonials | current vacancies | © 2011 - 2024 Your Company Name